Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Xiamen Amoytop Biotech Co., Ltd.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of non-small cell lung cancer or Breast cancer, and adequate for carboplatin combined with taxol or cyclophosphamide combined with pharmorubicin chemotherapy
Karnofsky Score ≥ 70
Life Expectancy \> 3 months
Age: 18~70yrs.
Peripheral blood test: WBC≥3.5×106/mm3, PLT≥100×106/mm3, ANC≥1.5×106/mm3; Normal bone marrow function; Bone marrow biopsy shows active hematopoietic without cancer cells.
Normal coagulation function, no evidences of hemorrhage tendency.
No exiting diseases or condition that may influence drug absorption, distribution, metabolism, and excretion.
Adequate liver, cardiac, kidney function. Indicators of liver function test ≤ 2.5ULN, Indicators of kidney function test ≤ 1ULN
Understand and voluntarily sign an informed consent form.
You may not be if
Pregnant or lactating females
Evidence of tumor metastasis in bone marrow
Lack insight due to tumor metastasis in the central nervous system
Prior bone marrow transplant or stem cell transplant
Infective symptom before enrollment into this study
Other malignancy history
Known hypersensitivity to any component of the drug(e.g. rh-G-CSF) that to be administered
Subject enrolled in any other investigational drug or device trial within 3 months of informed consent date
Drug abuser or alcoholist
Prior radiotherapy or expected to received radiotherapy
Unstable or uncontrolled cardiac or hypertension
Other conditions which in the opinion of the investigator preclude enrollment into the study